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Abstract 
Background: There are few rapid point-of-care tests (POCT) for tuberculosis (TB) for use in resource-constrained 
settings with high levels of human immunodeficiency virus (HIV). This hinders early tuberculosis (TB) treatment. This 
cross-sectional study evaluates the recently developed urine Determine tuberculosis lipoarabinomannan (TB LAM) 
antigen test. A total of 122 participants with signs and symptoms of TB, including 21 (17.1%) participants positive for 
HIV, were enrolled from September 2011 to March 2012 at three selected health centers in Addis Ababa, Ethiopia. 
Blood, sputum and urine samples were collected. Löwenstein-Jensen (LJ) solid culture was used as a gold standard to 
evaluate the performance of the Determine TB LAM antigen test. Data were analyzed using STATA (Statacorp LP, USA).
Results: Of the 122 participants with suspected TB, 35 (28.7%) had TB confirmed bacteriologically by LJ culture. The 
overall sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Determine TB LAM 
(for both HIV-positive and HIV-negative participants) was 37.1% (95% CI 21.5–55.1), 97.7% (95% CI 91.9–99.7), 86.7% 
(95% CI 59.5–98.3) and 79.4% (95% CI 70.5–86.6), respectively. However, in participants who were co-infected with 
TB and HIV, sensitivity, specificity, PPV and NPV were 55.6% (95% CI 21.2–86.3), 100% (95% CI 73.5–100), 100% (95% CI 
47.8–100) and 75.0% (95% CI 47.6–92.7). Moreover, the level of immunosuppression of the HIV-infected TB patients 
was found to have a significant association with the performance of Determine TB LAM (χ2 = 7.89, p = 0.002).
Conclusions: The Determine TB LAM test is a potential alternative in peripheral health settings for TB diagnosis in 
patients who are co-infected with HIV, with advanced immunosuppression.
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Background
The double burden of tuberculosis (TB) and HIV remains 
the greatest challenge to medicine and public health in 
developing countries. Ethiopia ranks seventh among 
the 22 high-burden TB countries [1, 2]. In the absence 
of an effective vaccine for TB in these countries, the 
control and ultimate elimination of this disease depends 
on prompt diagnosis and therapeutic intervention to 
minimize ongoing transmission [3, 4].
Current tools for TB diagnosis have serious limita-
tions like, poor speed, requiring high skilled experts and 
infrastructure and poor sensitivity, which cause delays 
in the diagnosis and treatment of active TB especially 
in individuals co-infected with HIV infection and smear 
negatives.
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Progress towards TB elimination has slowed. Revers-
ing this decline requires renewed efforts in the scale-up 
of early diagnosis and proper treatment [10, 11]. This 
requires prioritizing the development of POCT that are 
simple, accurate, inexpensive and easily established in 
resource-limited settings [12, 13]. Alere has recently 
developed the Determine TB LAM POCT. The test pro-
vides results by detecting the LAM antigen in urine sam-
ples using the lateral flow principle [14].
Determine TB LAM could useful in providing impor-
tant augmented sensitivity in settings where smear 
microscopy remains the only available microbiological 
test [15]. Though it requires further studies, the perfor-
mance of the test for diagnosis of TB in HIV-infected indi-
viduals is promising [14–19]. This study was conducted to 
fill the knowledge gap by evaluating the performance of 
Determine TB LAM for TB diagnosis in Ethiopia.
Method
Study setting and study participants
A cross-sectional study was carried out from Septem-
ber 2011 to March 2012 in three selected health centers 
(Saris, Wereda 6 and Wereda 7) in Addis Ababa, Ethio-
pia. These healthcare facilities are government-owned 
organizations that provide public health services includ-
ing TB and HIV diagnosis and treatment. Consecutively 
recruited participants were adults (≥18 years) visiting the 
health facilities with suspected TB who had one of the 
signs and symptoms of TB (current cough lasting at least 
2 weeks, bloody cough, fever, weight loss, chest pain, feel-
ing tired, night sweats, breath shortness), and who were 
voluntary for HIV testing and were naïve for highly active 
antiretroviral therapy (HAART) and anti-TB treatment 
were recruited consecutively. The study excluded partici-
pants who were severely ill (with critical conditions and 
unable to provide consent), those with chronic diseases 
(such as hypertension, diabetes mellitus, renal failure and 
cancer, which would act as confounding factors in the 
performance of the test in HIV-infected patients), preg-
nant women (pregnancy could be a confounding factor 
due to immunological shifts during pregnancy) and those 
under immunosuppressive treatments.
Sample size
A sample size of 100–200 is recommended for method 
validation experiments [20]. Therefore following judg-
ment sampling technique, a total of 122 patients with 




A structured questionnaire was prepared and socio-
demographic data including sex and age, and clinical 
data on body mass index (BMI) and TB-specific signs and 
symptoms, were collected by the clinician.
Laboratory procedures
Sample collection
Urine, expectorated sputum and blood were collected 
from each participant. All samples were transported 
to the national HIV and TB reference laboratory of the 
Ethiopian Public Health Institute (EPHI) for laboratory 
analysis.
Laboratory analysis
The Determine TB LAM test was performed by applying 
60 μL of fresh urine to the sample pad on the Determine 
TB LAM Ag strip (Alere international ltd, South Africa) 
and interpreted following the manufacturer’s instruc-
tions. Sputum samples were processed for Löwenstein-
Jensen (LJ) culture. Modified Petroff’s method was used 
to digest and decontaminate the sputum specimens. A 
100–200  μL aliquot of the sample was then inoculated 
into two tubes of LJ medium. The growth of the bacteria 
was read every week from 3 to 8 weeks according to the 
Standard operating procedures. Identification of Myco-
bacterium tuberculosis complex from other mycobacte-
rial species was done using TB Ag MPT64 rapid capilia 
test (Capilia TB-Neo, Japan). Sputum smears were also 
prepared from the sediment of processed specimen. The 
slides were coded, dried in air, heat fixed, and stained 
by the Ziehls Neelson (ZN) technique and examined 
for acid-fast bacillus (AFB) using 100×  oil immersion 
microscopy. In addition, blood samples were added to 
tubes containing fluorochrome-labeled antibodies and 
analyzed using FACS Caliber Flow cytometry analyzer 
for CD4 determination.
Statistical analysis
Data were analyzed using STATA version 10 analyti-
cal software. Determine TB LAM test sensitivity, speci-
ficity, and positive and negative predictive values were 
defined by comparing results with the gold-standard 
test for active TB, the sputum LJ culture. The presence 
of association of independent variables with the Deter-
mine TB LAM test performance was evaluated using the 
Chi squared test. p values less than 0.05 were considered 
significant.
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Results
Characteristics of participants
The 122 study participants had a median (IQR) age of 30 
(23–45) years; 68 (56%) were male (Table 1). Twenty-one 
(17.2%) of the participants enrolled were infected with 
HIV. The mean (standard deviation; SD) CD4 count was 
556 (307) cells/µL. The majority (56.6%) of the partici-
pants had a body mass index (BMI) in the normal range 
(18.5 < BMI < 24.99 kg/m2). The study participants were 
primarily screened for signs and symptoms of TB. All 
the study participants (100%) had a cough lasting at least 
2 weeks. Tiredness and chest pain were experienced in 82 
and 80% of the study participants, respectively. Weight 
loss, shortness of breath and coughing with blood were 
also observed in 67, 63 and 21% of the study participants, 
respectively.
Of the 122 participants with suspected TB, 21 (17.2%) 
were HIV positive. Thirty-five participants (28.7%) had 
TB bacteriologically confirmed by LJ culture. Of the LJ 
culture positives, 24/35 (68.6%) were sputum smear-neg-
ative, and 9 (25.7%) were HIV co-infected (Fig. 1).
Performance of urine Determine TB LAM test
The strength of the Determine TB LAM test to diagnose 
TB irrespective of patients’ HIV status was calculated. 
The Determine TB LAM test was positive in 15 (12.3%) 
of the 122 study participants and 2 of these 15 were LJ 
culture negative. We found the sensitivity, specificity, 
PPV, and NPV of Determine TB LAM to be 37.1% (95% 
CI 21.5–55.1), 97.7% (95% CI 91.9–99.7), 86.7% (95% CI 
59.5–98.3) and 79.4% (95% CI 70.5–86.6), respectively.
We compared the performance of the Determine TB 
LAM test with the currently available conventional TB 
diagnostic test at the peripheral level, the AFB smear 
microscopy. Seven participants who were TB negative 
by the conventional AFB smear microscopy were posi-
tive by the Determine TB LAM test. Of these, 5 were LJ 
culture positive and 2 were LJ culture negative. Interest-
ingly, when the two tests (AFB smear microscopy and 
Determine TB LAM test) were combined, 8 individuals 
were found to be positive and all were LJ culture posi-
tive (Table 2). We found significant association between 
smear status and Determine TB LAM test results 
(χ2 = 36.45, p < 0.001).
Performance of the Determine TB LAM test in HIV 
co‑infected participants
We also evaluated the effect of HIV infection on the per-
formance of the Determine TB LAM test for TB diag-
nosis. The sensitivity, specificity, PPV and NPV of the 
Determine TB LAM test in patients suspected of TB who 
were co-infected with HIV were 55.6% (95% CI 21.2–
86.3), 100% (95% CI 73.5–100), 100% (95% CI 47.8–100) 
and 75.0% (95% CI 47.6–92.7), respectively (Fig. 2).
Among the 21 patients with suspected TB who were 
HIV positive, 5 were TB positive by the Determine TB 
LAM test and 1 was positive by AFB smear microscopy. 
When the Determine TB LAM test and AFB were com-
pared with the gold standard LJ culture, the Determine 
TB LAM test was positive in 55.5%, but AFB was posi-
tive in 11.1%, of the HIV co-infected TB patients. This 
indicates the gap in the use of AFB microscopy in HIV-
infected TB patients.
Interestingly, we further stratified the 5 HIV-infected 
individuals who were Determine TB LAM test posi-
tive, but AFB smear negative, by their CD4 count (those 
with <200 cells per µL and those with ≥200 cells per µL)
to see if the performance of the Determine TB LAM test 
was affected by the level of immunosuppression. All 5 
HIV-infected individuals with a CD4 count of <200 cells 
per µL were positive by the Determine TB LAM test, but 
negative with AFB microscopy. However, the Determine 
TB LAM test was negative in all of the HIV-infected indi-
viduals with a CD4 count ≥200 cells per µL, and AFB was 




 Female 54 44
 Male 68 56
Age (year)
 Adults <65 112 92
 Adults ≥65 10 8
CD4 count (cells/µL)
 CD4 < 200 24 20
 CD4 ≥ 200 98 80
BMI category (kg/m2)
 BMI < 18.5 38 30.1
 18.5 < BMI < 24.99 69 56.6
 BMI ≥ 25 15 12.3
HIV status
 Positive 21 17.2
 Negative 101 82.8
Sign and symptoms for TB
 Current cough ≥2 weeks 122 100
 Bloody cough 26 21
 Fever 89 73
 Weight loss 82 67
 Chest pain 98 80
 Feeling tired 100 82
 Night sweats 85 70
 Breath shortness 77 63
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positive in 1 of these. We found significant associations 
between the performance of the Determine TB LAM test 
and HIV infection status (χ2 = 3.12, p < 0.04) and level of 
immunosuppression (χ2 = 7.89, p < 0.005).
Discussion
Searching for and evaluating TB diagnostic assays that 
are easily applied in developing countries challenged 
by the increased burden of TB and HIV infections is of 
worldwide importance. The Determine TB LAM test is 
a lateral-flow rapid point-of-care test developed recently 
by Alere. This method is developed for use where, due 
to resource constraints, there is limited availability of 
advanced assays. Studies evaluating the performance of 
Determine TB LAM in different geographical locations 
are limited. We evaluated the performance of this assay in 
response to this need. As our focus was the performance 
of the test in HIV-infected patients, we excluded those 
with factors that could confound the results of the study 
(chronic disease, pregnancy and immunosuppressive 
medications).
The overall sensitivity, specificity, PPV and NPV of 
the Determine TB LAM test to diagnose TB irrespec-
tive of patient HIV status found in this study was similar 
to the findings of recent studies [14–18]. Although AFB 
smear microscopy remains the conventional diagnostic 
tool for TB in resource-limited settings, its decreased 
sensitivity reinforces the need for additional point-of-
care assays in these settings. In our study, Determine TB 
LAM test detected TB in 5 (20.7%) individuals whose TB 
was missed by the conventional smear microscopy. This 
strongly suggests that Determine TB LAM may be used 
to address the challenges in diagnosing TB using AFB 
microscopy.
AFB done for 122 
(100%) 
LJ Culture was 
done for 122 
(100%) 
Test posive
= 35 (28.7%) 
Test negave
= 71 (71.3%)
All (100%) were screened for 
TB specific sign and symptoms 
Capilia done 
for 35 culture 
posives
Test posive
= 35 (100%) 
Test negave
= 0 
122 Volunteer TB suspects were enrolled
Determine TB 







= 15 (12.3) 
Test Negave
= 107 (87.7%)
Fig. 1 Tuberculosis diagnostic flow and diagnostic results of TB suspects
Table 2 Performance of Determine TB LAM test and smear microscopy, when combined and used alone for the diagnos-
ing TB suspects














All (n = 122) 31.4 (16.9–49.3) 98.9 (93.8–99.9) 37.1 (21.5–55.1) 97.7 (21.5–55.1) 72.7 (39.0–93.9) 100 (2.5–100)
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In this study, some individuals whose TB was missed by 
Determine TB LAM were detected as positive by smear 
microscopy, indicating the value of smear microscopy in 
diagnosing TB. However, an interesting additive effect 
occurred when combining the two peripheral diagnostic 
assays (smear microscopy and Determine TB LAM).
We found higher sensitivity than in a study conducted 
by Lawn et al. (which was 43.7%). This difference might 
be due to the fact that they used frozen samples and the 
effect of freezing urine samples is not well known [14, 
15]. In addition to the challenge of diagnosing smear-
negative TB, diagnosis of TB in HIV co-infected patients 
is another challenge to controlling TB in resource-lim-
ited settings. Rapid detection of active TB is essential 
for managing patients with advanced HIV infection as it 
permits earlier initiation of TB therapy and institution of 
infection control procedures in high-burden settings. In 
this study, the sensitivity of the Determine TB LAM test 
in HIV-infected patients was shown to be much better 
than in HIV-negative patients. Interestingly, sensitivity 
was strongly associated with patients’ CD4 cell counts, 
with the highest sensitivity recorded for those with 
advanced immunosuppression (CD4 count  <200 cells/
µL). This was comparable with other findings done on 
HIV HIV-infected TB patients [14–18].
In relation to this, the sensitivity of the conven-
tional diagnostic assay in high-burden settings (smear 
microscopy) is much lower compared with Determine 
TB LAM for diagnosis of TB in HIV-infected patients, 
especially those with advanced immunosuppression. 
Moreover studies have also indicated that the perfor-
mance of Determine TB LAM test was greater in patients 
with advanced lower CD4 count. This might be related 
with the fact that HIV-infected patients with advanced 
immunosuppression have more severe disease and a 
likely higher antigen burden of lipoarabinomannan anti-
gen in urine [12]. It might also be due to the changes in 
glomerular filtration secondary to HIV-related podocyte 
dysfunction [21].
Conclusion
We found the sensitivity of the Determine TB LAM test 
increased in patients with HIV co-infection. Thus, the 
Determine TB LAM test is a promising point-of-care 
assay for the diagnosis of smear-negative TB patients and 
HIV-infected individuals, especially those with advanced 
immunosuppression. Moreover, the combination of 
smear microscopy and Determine TB LAM tests could 
improve the diagnosis of TB in peripheral health settings. 
Further research in different groups including children 
and in resource-constrained settings in different geo-
graphical locations is warranted.
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Fig. 2 Sensitivity and specificity of Determine TB LAM test and smear 
microscopy; a among HIV co-infected individuals b among HIV nega-
tive individuals
Page 6 of 6Sahle et al. BMC Res Notes  (2017) 10:74 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ethics approval and consent to publish
The study protocol was evaluated and approved by the Ethical Clearance 
Committee of Department of Medical Laboratory Science (College of Health 
Sciences, Addis Ababa University) and the Science and Ethical Review Office of 
EPHI. Moreover, letters of cooperation were written to Addis Ababa Regional 
Health Bureau and TB program managers of the region to get permission to 
conduct the study in the health facilities of the region. Prior to conducting 
the study, the purpose and objective of the study were described to the study 
participants and written informed consent was obtained from each study 
participant. Personal identifiers were not used on data collection forms and 
confidentiality was maintained.
Funding
This study was supported by Ethiopian Public Health Institute and Addis 
Ababa University. We also received a donation of Determine TB LAM test kit 
from Alere. None of the sources played any role in the design, conduct, analy-
sis, interpretation or decision to publish these data.
Received: 17 March 2016   Accepted: 25 January 2017
References
 1. Myers J, Sepkowitz K. HIV/AIDS and TB. Amsterdam: Elsevier; 2008. p. 
421–30.
 2. World Health Organization. Global tuberculosis report 2014. http://www.
who.int/tb/publication/global_report/en/index.html. Accessed 12 Apr 
2015.
 3. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P. 
Tuberculosis Tuberculosis 1 control and elimination 2010–50: cure, care, 
and social development. Lancet. 2010;375:1814–29.
 4. Moise L, McMurry J, DeGroot AS. Mycobacterium tuberculosis. Vaccines for 
biodefense and emerging and neglected diseases. 2009; 1219–39.
 5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis 
of latent tuberculosis infection: areas of uncertainty and recommenda-
tions for research. Ann Intern Med. 2007;146:340–54.
 6. Lange C, Mori T. Advances in the diagnosis of tuberculosis. Respirology. 
2010;15:220–40.
 7. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and 
related glycoconjugates: structure, biogenesis and role in Mycobacterium 
tuberculosis physiology and host-pathogen interaction. FEMS Microbiol 
Rev. 2011;35:1–32.
 8. Wood R. Challenges of TB diagnosis and treatment in South Africa. 
SAJHIVMED. 2007;27:44–8.
 9. Tsigeweini AT, Hamasur B, Bjune G, Svenson S, Bjorvatn B. Diagnostic 
evaluation of urinary lipoarabinomannan at an Ethiopian Tuberculosis 
Centre. Scand J Infect Dis. 2001;33:279–84.
 10. Balcells ME, Pe´rez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, 
et al. A comparative study of two different methods for the detection 
of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis. 
2008;12:645–52.
 11. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-
ELISA assay for TB diagnosis in HIV-infected patients using urine and 
sputum samples. PLoS ONE. 2010;5:e9848.
 12. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine 
for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC 
Infect Dis. 2012;12:103.
 13. Cho SN, Brennan PJ. Tuberculosis: diagnostics. Tuberculosis. 
2007;87:S14–7.
 14. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabi-
nomannan detection in urine using a low-cost point-of-care diagnostic 
assay for HIV-associated tuberculosis. AIDS. 2012;26:1635–43.
 15. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-
cost, urine antigen, point-of-care screening assay for HIV-associated 
pulmonary tuberculosis before antiretroviral therapy: a descriptive study. 
Lancet Infect Dis. 2012;12:201–9.
 16. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the 
diagnosis of tuberculosis: current approaches, clinical applicability, and 
new developments. CurrOpinPulm Med. 2010;16:262–70.
 17. Peter JG, Theron G, van Zyl Smit R, et al. Diagnostic accuracy of a urine 
LAM strip-test for TB detection in HIV-infected hospitalized patients. Eur-
Respir J. 2012. doi:10.1183/09031936.00201711.
 18. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Diagnostic 
accuracy of a point-of-care urine test for tuberculosis screening among 
newly-diagnosed HIV-infected adults: a prospective, clinic-based study. 
BMC Infect Dis. 2014;14:110.
 19. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, Bassett IV. Value 
of urine lipoarabinomannan grade and second test for optimizing clinic-
based screening for HIV-associated pulmonary tuberculosis. J AcquirIm-
munDeficSyndr. 2014;68:274–80.
 20. Westgard OJ. The comparison of methods experiment. http://www.
westgard.com/lesson23.htm. Accessed 19 June 2013.
 21. Doublier S, Zennaro C, Spatola T, et al. HIV-1 Tat reduces nephrin in 
human podocytes: a potential mechanism for enhanced glomerular 
permeability in HIV-associated nephropathy. AIDS. 2007;21:423–32.
